Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

Gil I. Wolfe, Richard J. Barohn, Barbara M. Foster, Carlayne E Jackson, John T. Kissel, John W. Day, Charles A. Thornton, Sharon P. Nations, Wilson W. Bryan, Anthony A. Amato, Miriam L. Freimer, Gareth J. Parry

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)549-552
Number of pages4
JournalMuscle and Nerve
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Intravenous Immunoglobulins
Myasthenia Gravis
Randomized Controlled Trials
Placebos
Albumins
Equipment and Supplies

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Wolfe, G. I., Barohn, R. J., Foster, B. M., Jackson, C. E., Kissel, J. T., Day, J. W., ... Parry, G. J. (2002). Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle and Nerve, 26(4), 549-552. https://doi.org/10.1002/mus.10224

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. / Wolfe, Gil I.; Barohn, Richard J.; Foster, Barbara M.; Jackson, Carlayne E; Kissel, John T.; Day, John W.; Thornton, Charles A.; Nations, Sharon P.; Bryan, Wilson W.; Amato, Anthony A.; Freimer, Miriam L.; Parry, Gareth J.

In: Muscle and Nerve, Vol. 26, No. 4, 01.10.2002, p. 549-552.

Research output: Contribution to journalArticle

Wolfe, GI, Barohn, RJ, Foster, BM, Jackson, CE, Kissel, JT, Day, JW, Thornton, CA, Nations, SP, Bryan, WW, Amato, AA, Freimer, ML & Parry, GJ 2002, 'Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis', Muscle and Nerve, vol. 26, no. 4, pp. 549-552. https://doi.org/10.1002/mus.10224
Wolfe, Gil I. ; Barohn, Richard J. ; Foster, Barbara M. ; Jackson, Carlayne E ; Kissel, John T. ; Day, John W. ; Thornton, Charles A. ; Nations, Sharon P. ; Bryan, Wilson W. ; Amato, Anthony A. ; Freimer, Miriam L. ; Parry, Gareth J. / Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. In: Muscle and Nerve. 2002 ; Vol. 26, No. 4. pp. 549-552.
@article{6b99cc667e0848ab9ff504b68551b855,
title = "Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis",
abstract = "We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5{\%} albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.",
keywords = "Clinical trials, Intravenous immunoglobulin, Myasthenia gravis, Treatment",
author = "Wolfe, {Gil I.} and Barohn, {Richard J.} and Foster, {Barbara M.} and Jackson, {Carlayne E} and Kissel, {John T.} and Day, {John W.} and Thornton, {Charles A.} and Nations, {Sharon P.} and Bryan, {Wilson W.} and Amato, {Anthony A.} and Freimer, {Miriam L.} and Parry, {Gareth J.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1002/mus.10224",
language = "English",
volume = "26",
pages = "549--552",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

AU - Wolfe, Gil I.

AU - Barohn, Richard J.

AU - Foster, Barbara M.

AU - Jackson, Carlayne E

AU - Kissel, John T.

AU - Day, John W.

AU - Thornton, Charles A.

AU - Nations, Sharon P.

AU - Bryan, Wilson W.

AU - Amato, Anthony A.

AU - Freimer, Miriam L.

AU - Parry, Gareth J.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

AB - We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

KW - Clinical trials

KW - Intravenous immunoglobulin

KW - Myasthenia gravis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0036789453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036789453&partnerID=8YFLogxK

U2 - 10.1002/mus.10224

DO - 10.1002/mus.10224

M3 - Article

C2 - 12362423

AN - SCOPUS:0036789453

VL - 26

SP - 549

EP - 552

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -